What's in a name? An emerging framework for cancer-associated fibroblasts, myofibroblasts, and fibroblasts

Shakir Hasan; Matthew B Buechler

doi:10.1016/j.ccell.2022.10.018

What's in a name? An emerging framework for cancer-associated fibroblasts, myofibroblasts, and fibroblasts

Cancer Cell. 2022 Nov 14;40(11):1273-1275. doi: 10.1016/j.ccell.2022.10.018.

Authors

Shakir Hasan¹, Matthew B Buechler²

Affiliations

¹ Department of Immunology, University of Toronto, Toronto, ON, Canada.
² Department of Immunology, University of Toronto, Toronto, ON, Canada. Electronic address: matthew.buechler@utoronto.ca.

PMID: 36379205
DOI: 10.1016/j.ccell.2022.10.018

Abstract

In this issue of Cancer Cell, Foster and colleagues explore the heterogeneity in cancer-associated fibroblasts (CAFs) across tissue types and species, and they identify mechanoresponsive (MR), immunomodulatory (IM), and steady-state-like (SSL) CAFs. They show that altering the relative abundance of these CAF subtypes influences tumor progression and response to anti-tumor therapy.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cancer-Associated Fibroblasts*
Fibroblasts
Humans
Myofibroblasts
Neoplasms* / pathology
Tumor Microenvironment

Grants and funding

471606/CIHR/Canada